Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

348 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Differential body composition effects of protease inhibitors recommended for initial treatment of HIV infection: a randomized clinical trial.
Martinez E, Gonzalez-Cordon A, Ferrer E, Domingo P, Negredo E, Gutierrez F, Portilla J, Curran A, Podzamczer D, Ribera E, Murillas J, Bernardino JI, Santos I, Carton JA, Peraire J, Pich J, Deulofeu R, Perez I, Gatell JM; ATADAR Study Group. Martinez E, et al. Among authors: portilla j. Clin Infect Dis. 2015 Mar 1;60(5):811-20. doi: 10.1093/cid/ciu898. Epub 2014 Nov 10. Clin Infect Dis. 2015. PMID: 25389256 Free article. Clinical Trial.
Week 4 response predicts sustained virological response to all-oral direct-acting antiviral-based therapy in cirrhotic patients with hepatitis C virus genotype 3 infection.
Pineda JA, Morano-Amado LE, Granados R, Macías J, Téllez F, García-Deltoro M, Ríos MJ, Collado A, Delgado-Fernández M, Suárez-Santamaría M, Serrano M, Miralles-Álvarez C, Neukam K; Grupo de Estudio de Hepatitis Vírica, of the Sociedad Española de Enfermedades Infecciosas y Microbiología Clínica: GEHEP-SEIMC; Grupo de Estudio de Hepatitis Vírica, of the Sociedad Andaluza de Enfermedades Infecciosas y Microbiología Clínica: HEPAVIR / Red de Investigación en SIDA (RIS-HEP07). Pineda JA, et al. Clin Microbiol Infect. 2017 Jun;23(6):409.e5-409.e8. doi: 10.1016/j.cmi.2016.12.034. Epub 2017 Jan 28. Clin Microbiol Infect. 2017. PMID: 28137633 Free article.
Should we measure quality of life among people with HIV? A multicentre survey of physicians' opinions in Spain.
Izquierdo R, Suárez-García I, Gómez-García T, Marco-Sánchez C, Puente-Ferreiro J, Moreno C, Diaz A, Cabello-Clotet N, Vinuesa D, Blanco JL, Melús E, Gómez-Ayerbe C, Olalla J, Riera M, Bernardino JI, de López Bernaldo de Quirós JC, Moreno S, Jarrín I; CoRIS cohort. Izquierdo R, et al. HIV Med. 2024 Oct 25. doi: 10.1111/hiv.13726. Online ahead of print. HIV Med. 2024. PMID: 39455423
Long-term effectiveness and tolerability of dolutegravir/lamivudine in treatment-naive people with HIV: an analysis of a multicentre cohort at 96 weeks.
Suárez-García I, Alejos B, Moreno C, Martín Torres J, Masiá M, García-Fraile LJ, Riera M, Dalmau D, Rodríguez-Rosado R, Muga R, Moreno S, Jarrín I; CoRIS cohort. Suárez-García I, et al. J Antimicrob Chemother. 2024 Dec 23:dkae456. doi: 10.1093/jac/dkae456. Online ahead of print. J Antimicrob Chemother. 2024. PMID: 39710424
Valproic acid could help in the fight against COVID-19: A case-control study.
Moreno-Pérez O, Merino E, Manuel Ramos J, Carlos Rodríguez J, Diaz C, Mas P, Reus S, Sánchez-Martínez R, Boix V, Chico-Sánchez P, Sánchez-Payá J, Portilla J; On behalf COVID19-ALC research group. Moreno-Pérez O, et al. Among authors: portilla j. Neurologia (Engl Ed). 2024 Sep;39(7):549-554. doi: 10.1016/j.nrleng.2023.12.009. Neurologia (Engl Ed). 2024. PMID: 39232592 Free article.
Patient Participant Perspectives on Implementation of Long-Acting Cabotegravir and Rilpivirine: Results From the Cabotegravir and Rilpivirine Implementation Study in European Locations (CARISEL) Study.
Gutner CA, van der Valk M, Portilla J, Jeanmaire E, Belkhir L, Lutz T, DeMoor R, Trehan R, Scherzer J, Pascual-Bernáldez M, Ait-Khaled M, Hernandez B, de Ruiter A, Anand SB, Low EL, Hadi M, Barnes N, Sevdalis N, Mohammed P, Czarnogorski M. Gutner CA, et al. Among authors: portilla j. J Int Assoc Provid AIDS Care. 2024 Jan-Dec;23:23259582241269837. doi: 10.1177/23259582241269837. J Int Assoc Provid AIDS Care. 2024. PMID: 39221544 Free PMC article.
Dolutegravir/Lamivudine Efficacy and Safety Outcomes in People With HIV-1 With or Without Historical Resistance Results at Screening: 48-Week Pooled Analysis.
Scholten S, Cahn P, Portilla J, Bisshop F, Hodder S, Ruane P, Kaplan R, Wynne BR, Man CY, Grove R, Wang R, Jones B, Ait-Khaled M, Kisare M, Okoli C. Scholten S, et al. Among authors: portilla j. Open Forum Infect Dis. 2024 Jul 1;11(7):ofae365. doi: 10.1093/ofid/ofae365. eCollection 2024 Jul. Open Forum Infect Dis. 2024. PMID: 39015350 Free PMC article. Clinical Trial.
348 results